Use of unlicensed drugs and off-label drug use: focus on COVID-19
Introduction. In a crisis, like the COVID-19 outbreak, the strategy of experimental drug use in clinical practice increases the availability of potentially effective drugs that have not yet proven the opposite for patients with life-threatening diseases, despite the fact that such use is «off-label»...
Shranjeno v:
| Principais autores: | , , |
|---|---|
| Format: | Artigo |
| Jezik: | Russo |
| Izdano: |
Izdatelstvo OKI
2020-10-01
|
| Serija: | Качественная клиническая практика |
| Teme: | |
| Online dostop: | https://www.clinvest.ru/jour/article/view/542 |
| Oznake: |
Brez oznak, prvi označite!
|
